5 Essential Elements For "3
All enrolled patients who obtained a minimum of just one dose of zosuquidar or placebo during induction were being monitored for your incidence of adverse events (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions had been relevant to the duration of extended and substantial myelosuppression as is anticipated with i